A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors

Oncologist

Volumn 17, Issue 4, 2012, Pages 512-

  Kelly, Ronan J ^a   Robey, Robert W ^a   Chen, Clara C ^b   Draper, Deborah ^a   Luchenko, Victoria ^a   Barnett, Daryl ^c   Oldham, Robert K ^c   Caluag, Zinnah ^c   Frye, A Robin ^a   Steinberg, Seth M ^a   Fojo, Tito ^a   Bates, Susan E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CBA Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; CBT 1; CD56 ANTIGEN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; LIVER; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TREATMENT OUTCOME;

ABDOMINAL NEOPLASMS; ADULT; AGED; ALKALOIDS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PACLITAXEL; RADIOPHARMACEUTICALS; RHODAMINE 123; TECHNETIUM TC 99M SESTAMIBI;

EID: 84860139048     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0080     Document Type: Article

References (0)